Nano Labs Corp. announced that the company has signed a General Agreement with CIBNOR to collaborate on the commercial development of Nano Labs proprietary nanoparticle immune stimulatory delivery system technology for application in the aquaculture industry. The Joint Venture will initially focus on the development of an immune modulator for the prevention of White Spot Shrimp Virus disease in cultured shrimp.

Nano Labs has developed research on Polymer nanoparticle delivery technology and the experimental processes have already resulted in substantive and highly-promising test results. Working together, Nano Labs and CIBNOR will conduct commercial production technology validation and scaling to develop a commercial pilot program. CIBNOR will be providing resources (people, equipment and infrastructure) that are involved in the day-to-day work to further scale the technology for commercialization.

Both parties are working towards Specific Agreements resulting from this general cooperation agreement, including provisions to regulate intellectual property rights and participation of royalties. Nano Labs reserves the intellectual property of the technological developments, inventions and general knowledge that constitute the technology.